Additionally, mTOR inhibitors have demonstrated favorable outcomes in combination therapies for head and neck cancer [87], as monotherapy in esophagogastric cancer [88], and in estrogen receptor-positive (ER+) breast cancer patients after aromatase inhibitor (AI) failure [89]. This evidence concerns the gene ESR1 and breast carcinoma.